See every side of every news story
Published loading...Updated

Pfizer, Merck trial antiviral combos amid concerns over resistance to COVID-19 pills

Summary by Ground News
FDA greenlighted Paxlovid and molnupiravir as the first oral COVID-19 therapies for at-home use last month. However, the mutations that allow viruses to evade the antivirals are a real danger for drugs. The researchers from Pfizer (PFE) and Merck (MRK) have rebuffed such fears noting that they did not see drug resistance during their trials.

Bias Distribution

  • 100% of the sources lean Right
100% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in United States on Saturday, January 22, 2022.
Sources are mostly out of (0)